Stephen Sallan, MD

Department	Hematology/Oncology
Hospital Title	Chief of Staff, Dana-Farber Cancer Institute
Academic Title	Professor of Pediatrics
Phone	617-632-3316
Fax	617-632-5511
Email	Stephen Sallan
Location	Dana-Farber Cancer Institute 44 Binney Street Boston, MA 02115

Research Overview

Stephen Sallan's laboratory and clinical research focuses on the genetic heterogeneity and treatment of the most common malignancy of childhood, acute lymphoblastic leukemia (ALL). The researcher strives to understand the reasons for disease recurrence and drug resistance, develop new, more specific therapies, especially for the 20% of children whose leukemia is not cured by current therapies, and conduct all such research in the context of diminishing the toxicity of treatment. Current endeavors expand our investigations to adolescents and young adults with ALL and also extend the laboratory discoveries to other leukemias and lymphomas.

About Stephen Sallan

Dr. Sallan received his MD from Wayne State University School of Medicine. He completed residencies in pediatrics at the Boston Floating Hospital, Children's Hospital of Philadelphia, and the Hospital for Sick Children, London and a fellowship in pediatric oncology at Children's Hospital Boston and Dana-Farber Cancer Institute.

Dr Sallan received the Distinguished Alumni Award, Wayne State University School of Medicine, the James Carreras Prize for International Pediatrician of the Year, and the Boston Red Sox Biomedical All Star Award.

Key Publications

• Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636.

• Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896-904.

• Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh M, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute ALL Consortium Protocols. J Clin Onc 2007; 25:813-819.

• Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly K, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O’Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1995-2000). Leukemia 2010; 24:320-334.

• Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high risk acute lymphoblastic leukemia: Long-term follow-up of a prospective, randomized, multicentre trial. Lancet Oncology 2010; 11:950-961.

• Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Carmeron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT midline carcinoma by epidenomic reprogramming. Cancer Res 2011; 71:2686-2696.

• Grace R, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, DeAngelo DJ, Silverman LB. The frequency and management of asparagianse-related thrombosis in pediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute Consortium protocols. Brit J Haematol 2011; 152:452-459.

• Waber DP, Turek J, Queally JT, Catania L, Tobaey P, Romero I, Adams H, Alyman C, Jandet-Brunet C, Sallan SE, Silverman LB. Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL Consortium Protocol 95-01 at 5 years post diagnosis. Pediatric Blood and Cancer 2012; 58:758-765.